0%
Print report
Variant interpretation report

BRCA1 c.4253T>C, p.Leu1418Ser

NM_007294.4:c.4253T>C NP_009225.1:p.(Leu1418Ser) Missense · exon 12 View identifiers
Classification
Uncertain significance

Variant description:

The BRCA1 NM_007294.4:c.4253T>C (NP_009225.1:p.(Leu1418Ser)) missense variant has not previously been reported in somatic cancers (COSMIC). Based on available guidelines, this variant is considered to be a Variant of Uncertain Significance (VUS).

Five-step scale from benign to pathogenic. This variant is uncertain. Select a step to read what it means.

Uncertain.The recorded classification is uncertain significance.

In plain language

Gene-level background from the recorded interpretation.

About BRCA1

BRCA1 encodes a large nuclear protein that helps maintain genomic stability by coordinating the repair of DNA double-strand breaks through homologous recombination, and it also regulates transcription and the cell cycle. It acts as a tumor suppressor, working with proteins such as RAD51, BRCA2, BARD1, and PALB2 to preserve genome integrity. Inherited alterations in BRCA1 cause hereditary breast and ovarian cancer syndrome, with elevated risks of breast, ovarian, prostate, and pancreatic cancers, and biallelic loss underlies a rare form of Fanconi anemia. Because BRCA1-driven tumors rely on impaired DNA repair, they are treatable with PARP inhibitors.

LYFE Sciences is an AI system, and it can make mistakes. Criteria may be applied incorrectly, sources may be misread, and a confident-looking classification can still be wrong. Double-check every criterion and its underlying evidence before relying on any call.
01The reasoning

How it was classified

The recorded framework is ClinGen BRCA1 VCEP v1.2. The criteria and strengths shown below come from the saved assessment; this page does not recalculate the classification.

Recorded applied criteria

The applied criteria and their strengths are shown as assessed under the stated framework.

Pathogenic evidence criteria: 0 Benign evidence criteria: 1
Pathogenic criteria applied · 0

No pathogenic criterion marked as applied in the recorded assessment.

Benign criteria applied · 1
BP4Supporting
BP4 · supporting

Met at Supporting: BayesDel 0.0666657 is ≤0.15 and SpliceAI max delta 0.01 is ≤0.1 for this coiled-coil missense variant.

Recorded classification: Uncertain significance

VUS: BP4 (supporting) is the only applied criterion and satisfies neither an ENIGMA benign nor pathogenic combination rule.

02The sources

Evidence at a glance

Evidence summaries and captured source records, where available. Missing entries should not be interpreted as negative findings.

gnomAD v4.1
gnomAD v2.1
Population frequency
1 / 1,614,190 alleles

gnomAD v4.1: 1 / 1,614,190 alleles. Recorded AF 6.19506e-07. Recorded homozygote count 0.

gnomAD v2.1

Absent from gnomAD v2.1.

gnomAD-Canada

Absent from gnomAD-Canada v1.0.

No screenshot for this evidence
REVEL score
0.241 recorded score

Recorded REVEL score: 0.241. Refer to the recorded PP3/BP4 rationale for interpretation.

ClinVar submissions
4 reported laboratory submissions

4 Uncertain significance. ClinVar API review status: criteria provided, multiple submitters, no conflicts.

Context only ClinVar ↗
Functional evidence
Statement recorded

OncoKB did not identify variant-specific reviewed functional evidence for this variant; gene-level curated context is available for reviewer follow-up. BRCA1, a tumor suppressor involved in the DNA damage response, is mutated in various cancer types.

No listed criterion applied OncoKB ↗
COSMIC
Cancer Hotspots
Somatic evidence
No matching record reported

This variant has not previously been reported in somatic cancers (COSMIC).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.

For specialists

Technical detail

ACMG/AMP criteria under ClinGen BRCA1 VCEP v1.2, with the data and sources behind each one.

28 criteria with recorded statuses: 1 met · 5 not met · 8 not assessed · 14 not applicable. Open any row for the full reasoning, the rule and the evidence behind it.

Met Not met Not assessed Not applicable

For all three requested consequence/LOF criteria, the decisive VCEP applicability test is the variant consequence: NM_007294.4:c.4253T>C is a missense substitution producing p.(Leu1418Ser), not a null variant, protein-length-changing indel, stop-loss variant, or repetitive-region in-frame indel.

The VCEP governing files were searched using c.4253T>C, p.Leu1418Ser, and p.L1418S; no exact variant entry was found in the named governing tables/documents or the Houdayer paper text.

PS4 cannot be assessed because no verified variant-specific case-control counts, OR, confidence interval, or p-value are available.

PP4 and BP5 are not applicable because the exact Li et al. clinical-history LR is 1.47600089290012, within the VCEP non-informative range between the pathogenic and benign thresholds.

PP5 and BP6 are not applicable because the ENIGMA BRCA1 VCEP explicitly says not to use them.

PP3 is not met because neither applicable VCEP computational path reaches its threshold: BayesDel 0.0666657 is below 0.28 and SpliceAI 0.01 is below 0.2.

BP4 is met at Supporting strength because the missense variant lies in the coiled-coil domain and both required no-impact predictions satisfy the VCEP cutoffs: BayesDel 0.0666657 ≤0.15 and SpliceAI 0.01 ≤0.1.

BP7 is not applicable because the variant is missense inside a clinically important domain, not silent or intronic and not a missense/in-frame variant outside the domain under the BP7_Strong (RNA) path.

Population frequency evidence is below all benign-frequency thresholds, but PM2 remains unassigned because the VCEP-required regional read-depth and quality-control information is unavailable.

BS2 is not assessed because no qualifying phenotyped healthy-adult co-occurrence observation is available; frequency data alone cannot be converted into BS2 points under the VCEP appendix.

Met · 1

BP4 SupportingVCEPMet at Supporting: BayesDel 0.0666657 is ≤0.15 and SpliceAI max delta 0.01 is ≤0.1 for this coiled-coil missense variant. Details ▾Hide ▴
Reasoning

The variant is a missense substitution at p.(Leu1418Ser), within the VCEP-defined BRCA1 coiled-coil functional domain (aa 1391-1424), so the domain missense BP4 path applies. That path requires no predicted protein impact and no predicted splice impact: BayesDel no-AF ≤0.15 AND SpliceAI ≤0.1. The observed BayesDel score is 0.0666657 and the maximum SpliceAI delta score is 0.01; both satisfy the VCEP thresholds. No variant-specific pre-assigned BP4 code was found in SupplementaryTables_V1.2_2024-11-18.xlsx.txt, Specifications_V1.2_2024-11-18.docx.txt, Appendices_V1.2_2024-11-18.docx.txt, or PMID_22505045_Houdayer_2012_HumMutat.pdf.txt.

VCEP rule
Apply BP4 for: Missense or in-frame insertion, deletion or delins variants inside a (potentially) clinically important functional domain, and no predicted impact via protein change or splicing (BayesDel predicted No Impact AND SpliceAI ≤0.1). ... Missense Predictions (BayesDel no AF) BRCA1: No impact ≤ 0.15
Evidence considered
  • VCEP Specifications v1.2, BP4 rule for missense variants inside a potentially clinically important functional domain: BayesDel no-AF ≤0.15 AND SpliceAI ≤0.1.
  • Appendix J defines the BRCA1 coiled-coil domain as residues 1391-1424; p.(Leu1418Ser) is within that domain.
  • Case BayesDel no-AF result for NM_007294.4:c.4253T>C: 0.0666657, below the BRCA1 no-impact cutoff of 0.15.
  • Case SpliceAI result for NM_007294.4:c.4253T>C: maximum delta score 0.01, below the no-predicted-splicing-impact cutoff of 0.1.
Still missing
  • No c.4253T>C, p.Leu1418Ser, or p.L1418S entry or variant-specific pre-assigned BP4 code was found in SupplementaryTables_V1.2_2024-11-18.xlsx.txt.
  • No c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in Specifications_V1.2_2024-11-18.docx.txt.
  • No c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in Appendices_V1.2_2024-11-18.docx.txt.
  • No c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in PMID_22505045_Houdayer_2012_HumMutat.pdf.txt.
Sources

Not met · 5 · evaluated, threshold not reached

PS1 VCEPNot met: SpliceAI is 0.01, but no previously classified pathogenic variant producing the same Leu1418Ser substitution was identified. Details ▾Hide ▴
Reasoning

NM_007294.4:c.4253T>C produces p.Leu1418Ser and has SpliceAI max delta 0.01, satisfying the VCEP's no-predicted-splicing condition, but no previously classified pathogenic variant producing the same p.Leu1418Ser substitution was identified. The exact c.4253T>C, p.Leu1418Ser, and p.L1418S notations were searched in Specifications_Table4_V1.2_2024-11-18.xlsx, SupplementaryTables_V1.2_2024-11-18.xlsx, Specifications_V1.2_2024-11-18.docx, and Appendices_V1.2_2024-11-18.docx; no qualifying same-amino-acid pathogenic comparator was found. ClinVar reports the assessed variant as uncertain significance, not as the required pathogenic reference variant.

VCEP rule
Apply **PS1**, for predicted **missense** substitutions, where a previously classified **pathogenic** variant is considered to act via protein change (no confirmed or predicted effect on mRNA splicing (SpliceAI≤0.1)).
Evidence considered
  • Variant normalization: NM_007294.4:c.4253T>C produces NP_009225.1:p.(Leu1418Ser), also p.(L1418S).
  • SpliceAI result: maximum delta score 0.01, below the VCEP PS1 no-splicing threshold of 0.1.
  • ClinVar variation 246517 reports four clinical-laboratory submissions as uncertain significance; this is not a previously classified pathogenic comparator.
  • The governing VCEP files were searched under all three requested variant notations; no qualifying pathogenic same-amino-acid comparator was found.
Still missing
  • No qualifying same-amino-acid pathogenic comparator was found in Specifications_Table4_V1.2_2024-11-18.xlsx after searching c.4253T>C, p.Leu1418Ser, and p.L1418S.
  • No qualifying same-amino-acid pathogenic comparator was found in SupplementaryTables_V1.2_2024-11-18.xlsx after searching c.4253T>C, p.Leu1418Ser, and p.L1418S.
  • No qualifying same-amino-acid pathogenic comparator was found in Specifications_V1.2_2024-11-18.docx after searching c.4253T>C, p.Leu1418Ser, and p.L1418S.
  • No qualifying same-amino-acid pathogenic comparator was found in Appendices_V1.2_2024-11-18.docx after searching c.4253T>C, p.Leu1418Ser, and p.L1418S.
Sources
PP3 VCEPNot met: BayesDel 0.0666657 is below the VCEP PP3 threshold of ≥0.28 and SpliceAI 0.01 is below its ≥0.2 splice threshold. Details ▾Hide ▴
Reasoning

The variant is a missense substitution, p.(Leu1418Ser), at residue 1418 within the BRCA1 coiled-coil domain (aa 1391-1424), so both VCEP PP3 paths were evaluated. The protein-impact path requires BayesDel no-AF ≥0.28; the observed BayesDel score is 0.0666657, so that path is not met. The splice path applies to missense variants irrespective of functional-domain location and requires SpliceAI ≥0.2; the observed maximum SpliceAI delta score is 0.01, so that path is not met. No variant-specific pre-assigned PP3 code was found in SupplementaryTables_V1.2_2024-11-18.xlsx.txt, Specifications_V1.2_2024-11-18.docx.txt, Appendices_V1.2_2024-11-18.docx.txt, or PMID_22505045_Houdayer_2012_HumMutat.pdf.txt.

VCEP rule
Apply PP3 for missense or in-frame insertion, deletion or delins variants inside a (potentially) clinically important functional domain and predicted impact via protein change (BayesDel predicted Impact). ... Apply PP3 for predicted splicing (SpliceAI ≥0.2) for silent, missense/in-frame (irrespective of location in clinically important functional domain) and for intronic variants outside of the donor and acceptor ±1,2 positions. ... BRCA1: Impact ≥0.28
Evidence considered
  • VCEP Specifications v1.2, PP3 rule: missense or in-frame variants inside a potentially clinically important functional domain may use the protein-impact path with BayesDel predicted Impact; the BRCA1 threshold is Impact ≥0.28.
  • VCEP Specifications v1.2, PP3 rule: predicted splicing uses SpliceAI ≥0.2 for silent and missense/in-frame variants irrespective of location in a clinically important functional domain.
  • Appendix J defines the BRCA1 coiled-coil domain as residues 1391-1424; p.(Leu1418Ser) is within that domain.
  • Case SpliceAI result for NM_007294.4:c.4253T>C: DS_AG 0.01, DS_AL 0.001, DS_DG 0.001, DS_DL 0.0; maximum delta score 0.01.
  • Case BayesDel no-AF result for NM_007294.4:c.4253T>C: 0.0666657.
Still missing
  • No c.4253T>C, p.Leu1418Ser, or p.L1418S entry or variant-specific pre-assigned PP3 code was found in SupplementaryTables_V1.2_2024-11-18.xlsx.txt.
  • No c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in Specifications_V1.2_2024-11-18.docx.txt.
  • No c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in Appendices_V1.2_2024-11-18.docx.txt.
  • No c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in PMID_22505045_Houdayer_2012_HumMutat.pdf.txt.
Sources
BA1 VCEPNot met: the variant is absent from the specified non-cancer gnomAD datasets and the available all-comers AF is 6.19506e-07, far below the 0.001 BA1 threshold. Details ▾Hide ▴
Reasoning

The ENIGMA rule requires maximum filter allele frequency above 0.001 in a non-founder population of gnomAD v2.1 non-cancer exomes and/or gnomAD v3.1 non-cancer genomes, with read depth at least 20. The required non-cancer datasets report the variant as absent, so no qualifying allele frequency above 0.001 is present. The available all-comers gnomAD v4.1 result is also far below the threshold (total AF 6.19506e-07; 1/1,614,190 alleles; homozygotes 0; NFE AF 8.47438e-07), but it is not used to replace the VCEP's specified datasets. Read depth and FAF values are not supplied, so the conclusion is based on the reported absence in the specified datasets rather than a recalculated FAF.

VCEP rule
Filter allele frequency (FAF) is above 0.1% (FAF > 0.001) in gnomAD v2.1 (non-cancer, exome only subset) and/or gnomAD v3.1 (non-cancer), non-founder population(s). See Appendix G for details.
Evidence considered
  • ENIGMA BRCA1 specification v1.2 BA1 rule: apply using maximum filter allele frequency in a gnomAD non-founder population, with gnomAD v2.1 non-cancer exomes and gnomAD v3.1 non-cancer genomes preferred; threshold is >0.001 and read depth must be at least 20.
  • evidence.json source GNOMAD_V2_1_NON_CANCER: absent from gnomAD v2.1 non-cancer.
  • evidence.json source GNOMAD_V3_1_NON_CANCER: absent from gnomAD v3.1 non-cancer.
  • gnomAD v4.1 all-comers: total AF 6.19506e-07 (1/1,614,190 alleles), NFE AF 8.47438e-07 (1/1,180,028 alleles), homozygotes 0; this is below 0.001 and is not substituted for the VCEP-preferred datasets.
Still missing
  • No exact c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in SupplementaryTables_V1.2_2024-11-18.xlsx.txt.
  • No exact c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in Specifications_V1.2_2024-11-18.docx.txt.
  • No exact c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in Appendices_V1.2_2024-11-18.docx.txt.
  • No exact c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in HUMU-40-1557-s001.xlsx.txt.
  • Filter allele frequency and regional read-depth values for the required non-cancer datasets are not available.
Sources
BS1 VCEPNot met: the variant is absent from the specified non-cancer gnomAD datasets and the available all-comers AF 6.19506e-07 is below the 0.00002 BS1 Supporting threshold. Details ▾Hide ▴
Reasoning

The ENIGMA rule requires maximum filter allele frequency above 0.0001 for BS1 Strong, or above 0.00002 through 0.0001 for BS1 Supporting, in the specified non-founder non-cancer gnomAD populations, with read depth at least 20. The variant is absent from both specified non-cancer datasets, so neither frequency interval is met. The available all-comers gnomAD v4.1 total AF is 6.19506e-07, also below 0.00002, but does not replace the specified datasets.

VCEP rule
Filter allele frequency (FAF) is above 0.01% (FAF > 0.0001) in gnomAD v2.1 (non-cancer, exome only subset) and/or gnomAD v3.1 (non-cancer), non-founder population(s). See Appendix G for details. ... Filter allele frequency (FAF) is above 0.002% (FAF > 0.00002) and less than or equal to 0.01% (FAF ≤ 0.0001) in gnomAD v2.1 (non-cancer, exome only subset) and/or gnomAD v3.1 (non-cancer), non-founder population(s). See Appendix G for details.
Evidence considered
  • ENIGMA BRCA1 specification v1.2 BS1 rule: BS1 Strong requires FAF >0.0001; BS1 Supporting requires FAF >0.00002 and <=0.0001, using the specified non-cancer gnomAD populations and read depth at least 20.
  • evidence.json source GNOMAD_V2_1_NON_CANCER: absent from gnomAD v2.1 non-cancer.
  • evidence.json source GNOMAD_V3_1_NON_CANCER: absent from gnomAD v3.1 non-cancer.
  • gnomAD v4.1 all-comers: total AF 6.19506e-07; this is below the BS1 Supporting lower threshold and is not substituted for the VCEP-preferred datasets.
Still missing
  • No exact c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in SupplementaryTables_V1.2_2024-11-18.xlsx.txt.
  • No exact c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in Specifications_V1.2_2024-11-18.docx.txt.
  • No exact c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in Appendices_V1.2_2024-11-18.docx.txt.
  • No exact c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in HUMU-40-1557-s001.xlsx.txt.
  • Filter allele frequency and regional read-depth values for the required non-cancer datasets are not available.
Sources
BP1 VCEPNot met: SpliceAI is 0.01, but Leu1418 lies inside the VCEP coiled-coil domain spanning residues 1391-1424. Details ▾Hide ▴
Reasoning

The variant is missense and has no predicted splicing effect, with SpliceAI max delta 0.01 meeting the ≤0.1 condition. However, Leu1418 lies within the VCEP-defined BRCA1 coiled-coil functional domain at residues 1391-1424, so the required outside-domain condition for BP1_Strong is not met.

VCEP rule
Apply BP1_Strong for silent substitution, missense or in-frame insertion, deletion or delins variants outside a (potentially) clinically important functional domain AND no splicing predicted (SpliceAI ≤0.1). As justified in the appendices, (potentially) clinically important functional domains are defined as: BRCA1 RING aa 2-101; BRCA1 coiled-coil aa 1391-1424; BRCA1 BRCT repeats aa 1650-1857. See Specifications Figure1A and Appendix J for details.
Evidence considered
  • Variant consequence is missense: p.(Leu1418Ser).
  • SpliceAI maximum delta score is 0.01, satisfying the no-splicing-predicted condition of ≤0.1.
  • The VCEP-defined BRCA1 coiled-coil domain spans residues 1391-1424; residue 1418 is inside that domain, failing the BP1 outside-domain requirement.
Sources

Not assessed · 8 · no assessment recorded

PS3 VCEPNot assessed: ENIGMA Table 9 and ST4 contain no exact c.4253T>C functional-assay entry or calibrated PS3 assignment. Details ▾Hide ▴
Reasoning

PS3 cannot be assessed from the available VCEP-governed evidence. The ENIGMA Table 9 functional-assay file contains no entry for BRCA1 c.4253T>C, p.(Leu1418Ser), or p.(L1418S); the Supplementary Tables functional dataset (ST4) likewise contains no exact variant entry. The governing specification reserves PS3 for well-established functional studies supporting a damaging protein effect, with calibrated assay recommendations in Table 9. No variant-specific protein-function assay result, assay control comparison, calibrated code assignment, or publication-level functional finding for this variant is present in the consulted case evidence. The variant's missense consequence and low SpliceAI score do not establish PS3 under the VCEP rule.

VCEP rule
Well-established in vitro or in vivo functional studies supportive of a damaging effect. Apply PS3 for assays measuring effect via protein only OR mRNA and protein combined. See Specifications Table 9 for code recommendations from calibrated published assays. Also see Figure1C and Appendix E for details.
Evidence considered
  • ENIGMA Specifications Table 9, sheet Table9_BRCA12VCEP_specs: searches for c.4253T>C, p.Leu1418Ser, and p.L1418S returned no exact variant row or assigned PS3 code.
  • ENIGMA SupplementaryTables ST4 functional-assay dataset: searches for c.4253T>C, p.Leu1418Ser, and p.L1418S returned no exact variant row.
  • ENIGMA Specifications v1.2, PS3 functional-assay rule: PS3 is for well-established functional studies supportive of damaging effect, with protein-only or combined mRNA/protein assays and Table 9 calibrated recommendations.
  • ENIGMA Appendices v1.2, Appendix E: PS3 and BS3 are reserved for assigning variant impact on protein function and require consideration of assay design, variant location, and predicted or observed splicing.
  • HUMU-40-1557-s001.xlsx: search returned no exact c.4253T>C, p.Leu1418Ser, or p.L1418S entry; the separate clinical-history LR row is not functional assay evidence and was not used for PS3.
Still missing
  • Specifications_Table9_V1.2_2024-11-18.xlsx: no exact entry for c.4253T>C, p.Leu1418Ser, or p.L1418S.
  • SupplementaryTables_V1.2_2024-11-18.xlsx, ST4: no exact entry for c.4253T>C, p.Leu1418Ser, or p.L1418S.
  • Specifications_V1.2_2024-11-18.docx: governing PS3 rule was found, but no variant-specific functional result was found.
  • Appendices_V1.2_2024-11-18.docx: PS3/BS3 functional-assay guidance was found, but no variant-specific functional result was found.
  • HUMU-40-1557-s001.xlsx: no exact entry for c.4253T>C, p.Leu1418Ser, or p.L1418S.
Sources
PS4 VCEPNot assessed: no verified case-control counts, odds ratio, p-value, or confidence interval are available for c.4253T>C. Details ▾Hide ▴
Reasoning

The ENIGMA rule requires a matched case-control study with p-value <=0.05, OR >=4, and a lower confidence limit excluding 2.0. The available literature packet has no ai_classified_papers, and its only extracted full-text candidate, PMID:23788249, does not mention BRCA1 or c.4253T>C/p.Leu1418Ser/p.L1418S and provides no case-control data. No case or control counts are therefore available from the supplied evidence to calculate an OR or 95% CI. The governing VCEP files were searched for all three variant notations; no variant-level PS4 entry was found.

VCEP rule
The prevalence of the variant in affected individuals is significantly increased compared with the prevalence in controls. Case-control studies; p-value ≤0.05 and OR ≥4 (lower confidence interval excludes 2.0).
Evidence considered
  • ENIGMA Specifications v1.2 PS4 rule: "The prevalence of the variant in affected individuals is significantly increased compared with the prevalence in controls. Case-control studies; p-value ≤0.05 and OR ≥4 (lower confidence interval excludes 2.0)."
  • literature_pass.json reports ai_classified_papers=[]; its PS4 candidate list contains PMID 20301425, PMID 23788249, PMID 25394175, and PMID 26389258, but no verified variant-specific case-control extraction is present.
  • paper_extracts.json PMID:23788249: the paper does not mention BRCA1 or the exact variant and provides no variant-specific clinical or population data.
Still missing
  • No verified case-control cohort with affected-case and matched-control counts for this variant; OR, 95% CI, and p-value cannot be evaluated.
  • No entry for c.4253T>C, p.Leu1418Ser, or p.L1418S was found in Specifications_V1.2_2024-11-18.docx.txt.
  • No entry for c.4253T>C, p.Leu1418Ser, or p.L1418S was found in PMID_31853058_Li_2020_GeneticsInMedicine.pdf.txt.
  • No entry for c.4253T>C, p.Leu1418Ser, or p.L1418S was found in PMID_17924331_Easton_2007_AJHG.pdf.txt.
  • No entry for c.4253T>C, p.Leu1418Ser, or p.L1418S was found in PMID_31853058_methods_supplement.docx.txt.
Sources
PM2 VCEPNot assessed: the variant is absent from both required non-cancer gnomAD datasets, but the VCEP-required regional average read depth of at least 25 is unavailable. Details ▾Hide ▴
Reasoning

The ENIGMA PM2 Supporting rule requires absence from controls in both gnomAD v2.1 non-cancer exomes and gnomAD v3.1 non-cancer genomes, plus average regional read depth at least 25 and no quality-control failure. The variant is reported absent from both required non-cancer datasets, is a single-nucleotide substitution, and the all-comers gnomAD v4.1 record shows one allele and no homozygotes. However, the required regional average read depth and quality-control status are not available, so PM2 cannot be assigned.

VCEP rule
Absent from controls in an outbred population, from gnomAD v2.1 (non-cancer, exome only subset) and gnomAD v3.1 (non-cancer). Region around the variant must have an average read depth ≥25. See Appendix G for details.
Evidence considered
  • ENIGMA BRCA1 specification v1.2 PM2 Supporting rule: absence from gnomAD v2.1 non-cancer exomes and gnomAD v3.1 non-cancer genomes, with average regional read depth at least 25.
  • evidence.json source GNOMAD_V2_1_NON_CANCER: absent from gnomAD v2.1 non-cancer.
  • evidence.json source GNOMAD_V3_1_NON_CANCER: absent from gnomAD v3.1 non-cancer.
  • gnomAD v4.1 all-comers: total AC 1, total AN 1,614,190, total AF 6.19506e-07, homozygotes 0; this is supplemental context and does not establish the missing read-depth requirement.
Still missing
  • No exact c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in SupplementaryTables_V1.2_2024-11-18.xlsx.txt.
  • No exact c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in Specifications_V1.2_2024-11-18.docx.txt.
  • No exact c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in Appendices_V1.2_2024-11-18.docx.txt.
  • No exact c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in HUMU-40-1557-s001.xlsx.txt.
  • Regional average read depth and explicit quality-control status for the required non-cancer datasets are not available.
Sources
PM3 VCEPNot assessed: no documented Fanconi Anemia phenotype, same-gene co-occurring pathogenic/likely pathogenic variant, or trans phase is available to meet the VCEP PM3 pathway. Details ▾Hide ▴
Reasoning

The ENIGMA BRCA1 VCEP PM3 pathway requires a patient phenotype consistent with BRCA1-related Fanconi Anemia and a co-occurring variant in the same gene, with points assigned according to the phase and phenotype-specific Table 6 rules. The available case evidence does not document a Fanconi Anemia phenotype, an independently classified same-gene pathogenic/likely pathogenic co-occurring variant, an affected proband observation, or phase as in trans, cis, or unknown for this variant. Therefore, the PM3 evidence requirements cannot be evaluated and no PM3 strength is assigned.

VCEP rule
For recessive disorders, detected in trans with a pathogenic variant. ... Apply for patient with phenotype consistent with BRCA1- or BRCA2-related Fanconi Anemia (FA), and co-occurrent variants in the same gene. ... Phenotype is considered consistent with BRCA1- or BRCA2-related FA if: ... (i) Increased chromosome breakage (DEB, MMC, or spontaneous) and at least one clinical feature indicative of BRCA1/2-related FA, categorized under: physical features, pathology and laboratory findings, cancer diagnosis ≤5yr. ... (ii) Result unknown for chromosome breakage, and at least two clinical features indicative of BRCA1/2-related FA under at least two of the three categories: physical features, pathology and laboratory findings, cancer diagnosis ≤5yr. ... See Table 6 for approach to assign points per proband, and final PM3 code assignment based on the sum of PM3-related points.
Evidence considered
  • ENIGMA VCEP Specifications Table 1 PM3 rule: PM3 is for a patient with phenotype consistent with BRCA1- or BRCA2-related Fanconi Anemia and co-occurrent variants in the same gene; the case evidence contains no qualifying phenotype, same-gene co-occurring P/LP variant, or phase observation.
  • ENIGMA VCEP Specifications Table 6: PM3-related points are assigned per proband according to whether the P/LP variant is in trans or homozygous versus phase unknown, and final PM3 strength depends on the summed points.
Still missing
  • No affected-proband observation with a phenotype consistent with BRCA1-related Fanconi Anemia is documented for NM_007294.4:c.4253T>C (p.Leu1418Ser; p.L1418S).
  • No same-gene co-occurring pathogenic or likely pathogenic variant and no phase evidence establishing trans, cis, or unknown phase are documented.
  • Searched Specifications_V1.2_2024-11-18.docx.txt for c.4253T>C, p.Leu1418Ser, and p.L1418S; no variant-specific entry was found.
Sources
PP1 VCEPNot assessed: no quantitative co-segregation LR for multiple affected relatives is available; the only located LR is clinical-history LR 1.47600089290012, not PP1 evidence. Details ▾Hide ▴
Reasoning

PP1 requires quantitative co-segregation with disease in multiple affected family members and a Bayes-score likelihood ratio. The available case evidence contains no proband-level pedigree, affected-relative genotypes and phenotypes, meioses, or quantitative co-segregation analysis for NM_007294.4:c.4253T>C; the Li et al. clinical-history row has N_Probands=1 and LR=1.47600089290012 but is a clinical-history LR, not a co-segregation analysis, and therefore cannot establish PP1. The exact-variant searches found no entry in Specifications_V1.2_2024-11-18.docx.txt or HUMU-40-1557-s001.xlsx.txt.

VCEP rule
Co-segregation with disease in multiple affected family members ... See Appendix I for details. ... Apply weight as per Bayes Score: ... PP1 - LR ≥2.08:1 ... PP1_Moderate – LR≥4.3:1 ... PP1_Strong – LR≥18.7:1 ... PP1_Very Strong – LR≥350:1
Evidence considered
  • The ENIGMA specification requires co-segregation with disease in multiple affected family members measured by a quantitative co-segregation analysis method and assigns PP1 weight by Bayes Score: PP1 LR ≥2.08:1, PP1_Moderate LR ≥4.3:1, PP1_Strong LR ≥18.7:1, and PP1_Very Strong LR ≥350:1.
  • Li et al. 2020 Supplementary Table 3, exact BRCA1 c.4253T>C row: LOG(LR)=0.1690866202116013, N_Probands=1, LR=1.47600089290012; this is a clinical-history LR and is not a quantitative co-segregation LR for PP1.
  • No pedigree-level segregation data or quantitative PP1 analysis was present in the case-evidence bundle.
Still missing
  • A quantitative co-segregation analysis or sufficient pedigree-level data for multiple affected family members is missing.
  • No proband/relative genotype, phenotype, phase, meiosis, or non-segregation details are available in the case-evidence bundle.
  • No c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in Specifications_V1.2_2024-11-18.docx.txt.
  • No c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in HUMU-40-1557-s001.xlsx.txt.
Sources
BS2 VCEPNot assessed: no qualifying healthy-adult clinical observation or same-gene pathogenic co-occurrence is available, and gnomAD frequency data cannot supply BS2 points. Details ▾Hide ▴
Reasoning

The ENIGMA BS2 rule requires observation in a healthy adult with the relevant dominant heterozygous state, and its BRCA1-specific implementation requires co-occurrence with a pathogenic or likely pathogenic variant in the same gene, absence of Fanconi Anemia features, phenotyped individuals, and point-based assignment. The case contains no such clinical observation or co-occurrence evidence. The gnomAD result has zero homozygotes, and the VCEP explicitly excludes frequency-code data from BS2 point assignment.

VCEP rule
Observed in a healthy adult individual for a recessive (homozygous), dominant (heterozygous), or X-linked (hemizygous) disorder, with full penetrance expected at an early age ... Applied in absence of features of recessive disease, namely Fanconi Anemia phenotype. ... See Table 8 for approach to assign points per proband, and final BS2 code assignment based on the sum of BS2-related points.
Evidence considered
  • ENIGMA BRCA1 specification v1.2: BS2 is applied in the absence of Fanconi Anemia features and uses Table 8 point assignment for co-occurrence with a pathogenic or likely pathogenic variant in the same gene.
  • Appendix H states that BS2 applies only to phenotyped individuals from clinical or research cohorts and is not to be applied to data used for frequency-based codes.
  • gnomAD v4.1: homozygotes = 0; this frequency observation is not a qualifying BS2 clinical observation.
Still missing
  • No exact c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in SupplementaryTables_V1.2_2024-11-18.xlsx.txt.
  • No exact c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in Specifications_V1.2_2024-11-18.docx.txt.
  • No exact c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in Appendices_V1.2_2024-11-18.docx.txt.
  • No exact c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in HUMU-40-1557-s001.xlsx.txt.
  • No phenotyped healthy-adult BS2 observations, same-gene pathogenic co-occurrence, or Fanconi Anemia assessment are available.
Sources
BS3 VCEPNot assessed: ENIGMA Table 9 and ST4 contain no exact c.4253T>C functional-assay entry or calibrated BS3 assignment. Details ▾Hide ▴
Reasoning

BS3 cannot be assessed from the available VCEP-governed evidence. The ENIGMA Table 9 functional-assay file contains no entry for BRCA1 c.4253T>C, p.(Leu1418Ser), or p.(L1418S); the Supplementary Tables functional dataset (ST4) likewise contains no exact variant entry. The governing specification reserves BS3 for well-established functional studies showing no damaging effect on protein function, with calibrated assay recommendations in Table 9. No variant-specific benign functional assay result, assay control comparison, calibrated code assignment, or publication-level functional finding for this variant is present in the consulted case evidence. The variant's missense consequence and low SpliceAI score do not establish BS3 under the VCEP rule.

VCEP rule
Well-established in vitro or in vivo functional studies shows no damaging effect on protein function. Assay measures effect via protein only OR mRNA and protein combined. See Specifications Table 9 for code recommendations from calibrated published assays. Also see Figure1C and Appendix E for details.
Evidence considered
  • ENIGMA Specifications Table 9, sheet Table9_BRCA12VCEP_specs: searches for c.4253T>C, p.Leu1418Ser, and p.L1418S returned no exact variant row or assigned BS3 code.
  • ENIGMA SupplementaryTables ST4 functional-assay dataset: searches for c.4253T>C, p.Leu1418Ser, and p.L1418S returned no exact variant row.
  • ENIGMA Specifications v1.2, BS3 functional-assay rule: BS3 is for well-established functional studies showing no damaging effect on protein function, with protein-only or combined mRNA/protein assays and Table 9 calibrated recommendations.
  • ENIGMA Appendices v1.2, Appendix E: PS3 and BS3 are reserved for assigning variant impact on protein function and require consideration of assay design, variant location, and predicted or observed splicing.
  • HUMU-40-1557-s001.xlsx: search returned no exact c.4253T>C, p.Leu1418Ser, or p.L1418S entry; the separate clinical-history LR row is not functional assay evidence and was not used for BS3.
Still missing
  • Specifications_Table9_V1.2_2024-11-18.xlsx: no exact entry for c.4253T>C, p.Leu1418Ser, or p.L1418S.
  • SupplementaryTables_V1.2_2024-11-18.xlsx, ST4: no exact entry for c.4253T>C, p.Leu1418Ser, or p.L1418S.
  • Specifications_V1.2_2024-11-18.docx: governing BS3 rule was found, but no variant-specific functional result was found.
  • Appendices_V1.2_2024-11-18.docx: PS3/BS3 functional-assay guidance was found, but no variant-specific functional result was found.
  • HUMU-40-1557-s001.xlsx: no exact entry for c.4253T>C, p.Leu1418Ser, or p.L1418S.
Sources
BS4 VCEPNot assessed: no quantitative non-segregation LR or affected-relative genotype data is available to meet the ENIGMA BS4 thresholds. Details ▾Hide ▴
Reasoning

BS4 requires lack of segregation in affected family members measured by a quantitative co-segregation analysis method and a Bayes-score likelihood ratio. The available case evidence contains no affected-relative genotypes, phenotypes, meioses, pedigree, or quantitative non-segregation analysis for NM_007294.4:c.4253T>C. The exact-variant searches found no entry in Specifications_V1.2_2024-11-18.docx.txt or HUMU-40-1557-s001.xlsx.txt, so BS4 cannot be assigned.

VCEP rule
Lack of segregation in affected members of a family. ... See Appendix I. ... Apply weight as per Bayes Score: ... BS4_Supporting - LR ≤0.48 to >0.23:1 ... BS4_Moderate - LR ≤0.23:1 ... BS4 - LR ≤0.05:1 ... BS4_Very strong – LR ≤0.00285:1
Evidence considered
  • The ENIGMA specification requires lack of segregation in affected family members measured by a quantitative co-segregation analysis method and assigns BS4 weight by Bayes Score: BS4_Supporting LR ≤0.48 to >0.23:1, BS4_Moderate LR ≤0.23:1, BS4 LR ≤0.05:1, and BS4_Very strong LR ≤0.00285:1.
  • No quantitative non-segregation LR, pedigree, or affected-relative genotype/phenotype evidence was present in the case-evidence bundle.
  • Exact-variant searches for c.4253T>C, p.Leu1418Ser, and p.L1418S were performed in Specifications_V1.2_2024-11-18.docx.txt and HUMU-40-1557-s001.xlsx.txt; no entry was found.
Still missing
  • A quantitative non-segregation analysis or sufficient affected-family-member genotype and phenotype data is missing.
  • No pedigree, relative testing, meiosis, or affected-member non-segregation details are available in the case-evidence bundle.
  • No c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in Specifications_V1.2_2024-11-18.docx.txt.
  • No c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in HUMU-40-1557-s001.xlsx.txt.
Sources
Not applicable · 14· recorded as not applicable Show reasons ▾Hide reasons ▴
PVS1 N/ANot applicable: c.4253T>C is a missense variant, whereas the ENIGMA PVS1 rule applies to null variants such as nonsense, frameshift, canonical splice-site, initiation-codon, or exon-loss variants. Details ▾Hide ▴
Reasoning

NM_007294.4:c.4253T>C is a missense substitution, NP_009225.1:p.(Leu1418Ser) (p.(L1418S)), in BRCA1 exon 12 (legacy exon 13), not a nonsense, frameshift, initiation-codon, canonical ±1/2 splice-site, or exon deletion/duplication variant. The ENIGMA VCEP PVS1 rule is restricted to null variants, and Table 4 is the exon-level decision table for initiation, nonsense/frameshift, deletion, duplication, and canonical splice-site variants; it contains no c.4253T>C, p.Leu1418Ser, or p.L1418S entry. Therefore PVS1 is not applicable; no NMD or PVS1 strength-tier assignment is relevant to this missense variant.

VCEP rule
Null variant in a gene where loss of function is a known mechanism of disease. ... In alignment with SVI recommendations for PVS1 code application, evidence strength and description has been separated for different variant types. Apply according to PVS1 flowchart, which considers knowledge of clinically important functional domains.
Evidence considered
  • Case normalization: NM_007294.4:c.4253T>C produces NP_009225.1:p.(Leu1418Ser), also p.(L1418S), and is classified in the case evidence as a missense variant in exon 12.
  • ENIGMA Specifications v1.2, Table 1, PVS1 entry: the rule is for a null variant in a gene where loss of function is a known mechanism of disease, with application according to the PVS1 flowchart.
  • ENIGMA Specifications v1.2, Table 4: the searched exon-level PVS1 table lists initiation, PTC/nonsense, deletion, duplication, and canonical donor/acceptor ±1,2 variant classes; no notation of this missense variant was present.
  • ENIGMA Appendices v1.2, Appendix C, BRCA1 domain catalogue: Leu1418 is within the coiled-coil region (aa 1391-1424), but that missense/domain context does not convert the variant into a PVS1 null variant.
Still missing
  • No c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in Specifications_Table4_V1.2_2024-11-18.xlsx.txt; the searched table covers null and canonical splice-site PVS1 decision-tree variants, not missense substitutions.
  • No c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in Specifications_V1.2_2024-11-18.docx.txt.
  • No c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in Appendices_V1.2_2024-11-18.docx.txt.
  • No c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in PMID_22505045_Houdayer_2012_HumMutat.pdf.txt.
Sources
PS2 VCEPNot applicable: the ENIGMA VCEP says PS2 must not be used because de novo occurrences lack calibrated predictive value for BRCA1/2-related cancers. Details ▾Hide ▴
Reasoning

The ENIGMA BRCA1 VCEP explicitly designates PS2 as not to be used because BRCA1/2-related cancers occur relatively commonly and there is no information to calibrate the predictive capacity of de novo occurrences. No variant-specific de novo evidence was identified; the exact-variant searches found no entry in Specifications_V1.2_2024-11-18.docx.txt or HUMU-40-1557-s001.xlsx.txt.

VCEP rule
De novo (paternity confirmed) in a patient with the disease and no family history. ... Do not use ... BRCA1/2-related cancers occur relatively commonly. No information to calibrate the predictive capacity of de novo occurrences.
Evidence considered
  • The CSPEC entry for PS2 is 'Not Applicable'.
  • The governing specification states: 'De novo (paternity confirmed) in a patient with the disease and no family history.' followed by 'Do not use' because 'BRCA1/2-related cancers occur relatively commonly. No information to calibrate the predictive capacity of de novo occurrences.'
  • Exact-variant searches for c.4253T>C, p.Leu1418Ser, and p.L1418S were performed in Specifications_V1.2_2024-11-18.docx.txt and HUMU-40-1557-s001.xlsx.txt; no entry was found.
Still missing
  • No variant-specific de novo occurrence, disease phenotype, family-history, or parental-testing evidence was provided in the case-evidence bundle.
  • No c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in Specifications_V1.2_2024-11-18.docx.txt.
  • No c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in HUMU-40-1557-s001.xlsx.txt.
Sources
PM1 VCEPNot applicable: residue 1418 lies in the 1391-1424 coiled-coil domain, but ENIGMA explicitly marks PM1 not applicable and redirects this evidence to other criteria. Details ▾Hide ▴
Reasoning

Residue 1418 lies within the ENIGMA-defined BRCA1 coiled-coil domain at residues 1391-1424, and the hotspot search found no statistically significant hotspot. However, the BRCA1 VCEP explicitly marks PM1 as not applicable and directs domain-related missense evidence to BP1, BP4, and PP3 instead; therefore PM1 cannot be assigned.

VCEP rule
N/A. Informed by clinically calibrated bioinformatic prior probability of pathogenicity for missense alterations – missense predictions only apply if a variant is located in a (potentially) clinically important functional domain. Evaluate under BP1, BP4, PP3.
Evidence considered
  • ENIGMA Appendix C/J domain definition checked: BRCA1 coiled-coil residues 1391-1424; Leu1418 is inside this domain.
  • The case hotspot result reports no statistically significant hotspot for BRCA1 L1418.
  • The VCEP PM1 entry states that PM1 is not applicable and that the information is considered through BP1, BP4, and PP3.
Sources
PM4 VCEPNot applicable: Leu1418Ser is a single-residue substitution and causes no protein-length change from an in-frame indel or stop-loss variant. Details ▾Hide ▴
Reasoning

The variant is a single amino-acid missense substitution, Leu1418Ser, and does not produce a protein-length change from an in-frame deletion, in-frame insertion, or stop-loss event. The ENIGMA VCEP PM4 definition is limited to those protein-length changes and stop-loss variants; PM4 is therefore not applicable.

VCEP rule
Protein length changes due to in-frame deletions/insertions in a non-repeat region or stop-loss variants.
Evidence considered
  • Case normalization: NP_009225.1:p.(Leu1418Ser) is a missense substitution with no in-frame deletion, insertion, delins, or stop-loss consequence.
  • ENIGMA Specifications v1.2, Table 1, PM4 entry: 'Protein length changes due to in-frame deletions/insertions in a non-repeat region or stop-loss variants.'
Still missing
  • No c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in Specifications_V1.2_2024-11-18.docx.txt.
  • No c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in Appendices_V1.2_2024-11-18.docx.txt.
  • No c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in Specifications_Table4_V1.2_2024-11-18.xlsx.txt.
  • No c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in PMID_22505045_Houdayer_2012_HumMutat.pdf.txt.
Sources
PM5 N/ANot applicable: PM5 is restricted to genomic PTC changes, whereas c.4253T>C is a missense substitution producing Leu1418Ser. Details ▾Hide ▴
Reasoning

The assessed variant is a missense substitution, whereas the ENIGMA BRCA1 v1.2 PM5 implementation is restricted to genomic protein-termination-codon changes and exon-specific PM5_PTC weighting. The variant is not a PTC change, so PM5 is not applicable.

VCEP rule
Only applied to genomic PTC changes (not splicing). Weight determined by exon where the termination codon occurs (may not be the same exon as the variant position). See Specifications Table 4, provided as a separate searchable excel file, for PM5_PTC codes applicable for predicted termination codon variants - organized by exon.
Evidence considered
  • Variant consequence is missense: NM_007294.4:c.4253T>C, p.(Leu1418Ser).
  • The ENIGMA PM5 rule states that PM5 is only applied to genomic PTC changes, with weight determined by the exon where the termination codon occurs.
  • The governing Table 4 and Supplementary Tables files were searched under c.4253T>C, p.Leu1418Ser, and p.L1418S; no exact variant entry was found.
Still missing
  • No exact c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in Specifications_Table4_V1.2_2024-11-18.xlsx.
  • No exact c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in SupplementaryTables_V1.2_2024-11-18.xlsx.
  • No exact c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in Specifications_V1.2_2024-11-18.docx.
  • No exact c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in Appendices_V1.2_2024-11-18.docx.
Sources
PM6 VCEPNot applicable: the ENIGMA VCEP says PM6 must not be used because unconfirmed de novo occurrences lack calibrated predictive value for BRCA1/2-related cancers. Details ▾Hide ▴
Reasoning

The ENIGMA BRCA1 VCEP explicitly designates PM6 as not to be used because BRCA1/2-related cancers occur relatively commonly and there is no information to calibrate the predictive capacity of de novo occurrences without confirmed paternity and maternity. No variant-specific de novo evidence was identified; the exact-variant searches found no entry in Specifications_V1.2_2024-11-18.docx.txt or HUMU-40-1557-s001.xlsx.txt.

VCEP rule
Confirmed de novo without confirmation of paternity and maternity. ... Do not use ... BRCA1/2-related cancers occur relatively commonly. No information to calibrate the predictive capacity of de novo occurrences.
Evidence considered
  • The CSPEC entry for PM6 is 'Not Applicable'.
  • The governing specification states: 'Confirmed de novo without confirmation of paternity and maternity.' followed by 'Do not use' because 'BRCA1/2-related cancers occur relatively commonly. No information to calibrate the predictive capacity of de novo occurrences.'
  • Exact-variant searches for c.4253T>C, p.Leu1418Ser, and p.L1418S were performed in Specifications_V1.2_2024-11-18.docx.txt and HUMU-40-1557-s001.xlsx.txt; no entry was found.
Still missing
  • No variant-specific de novo occurrence or parental-testing evidence was provided in the case-evidence bundle.
  • No c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in Specifications_V1.2_2024-11-18.docx.txt.
  • No c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in HUMU-40-1557-s001.xlsx.txt.
Sources
PP2 VCEPNot applicable: ENIGMA states that missense variants are not a common mechanism of pathogenicity for BRCA1 and BRCA2. Details ▾Hide ▴
Reasoning

The ENIGMA BRCA1 VCEP explicitly marks PP2 as not applicable and states that missense variants are not a common mechanism of pathogenicity for BRCA1 and BRCA2.

VCEP rule
N/A. Missense variants are not a common mechanism of pathogenicity for BRCA1 and BRCA2.
Evidence considered
  • The VCEP PP2 entry is marked not applicable because missense variants are not a common mechanism of pathogenicity for BRCA1 and BRCA2.
Sources
PP4 N/ANot applicable: Li et al. clinical-history LR 1.47600089290012 is below the PP4 supporting threshold of 2.08. Details ▾Hide ▴
Reasoning

The governing ENIGMA rule permits PP4 only for combined multifactorial clinical likelihood ratios. The exact Li et al. 2020 row for BRCA1 c.4253T>C reports LOG(LR)=0.1690866202116013 and LR=1.47600089290012. The VCEP supporting threshold is LR >=2.08:1, so 1.47600089290012 >= 2.08? no. The VCEP also states that combined LR >0.48 and <2.08 is not informative and PP4 is not applicable.

VCEP rule
Breast cancer is very common and has a high degree of genetic heterogeneity (caused by pathogenic variants in numerous genes). Use ONLY to capture combined LR towards pathogenicity, based on multifactorial likelihood clinical data. PP4 - LR ≥2.08:1 See Specifications Table7 and Appendix B for details.
Evidence considered
  • Li et al. 2020 Supplementary Table 3, Sheet1 exact match: BRCA1 c.4253T>C; LOG(LR)=0.1690866202116013; N_Probands=1; LR=1.47600089290012.
  • The governing PP4 operator is ≥; explicit comparison: 1.47600089290012 ≥ 2.08? no.
  • ENIGMA v1.2 states that combined LR >0.48 and <2.08 is not informative and PP4 is not applicable.
Still missing
  • No PP4-applicable combined multifactorial LR beyond the exact Li et al. clinical-history component was identified.
  • No entry for c.4253T>C, p.Leu1418Ser, or p.L1418S was found in Specifications_V1.2_2024-11-18.docx.txt, PMID_31853058_Li_2020_GeneticsInMedicine.pdf.txt, PMID_17924331_Easton_2007_AJHG.pdf.txt, or PMID_31853058_methods_supplement.docx.txt.
Sources
PP5 VCEPNot applicable: the ENIGMA BRCA1 VCEP explicitly states that PP5 should not be used. Details ▾Hide ▴
Reasoning

The ENIGMA BRCA1 VCEP explicitly says PP5 is not to be used. No pathogenic reputable-source report can override that VCEP applicability decision.

VCEP rule
Reputable source recently reports variant as pathogenic but the evidence is not available to the laboratory to perform an independent evaluation. Do not use
Evidence considered
  • ENIGMA Specifications v1.2 PP5 entry: "Reputable source recently reports variant as pathogenic but the evidence is not available to the laboratory to perform an independent evaluation." followed by "Do not use".
Still missing
  • No entry for c.4253T>C, p.Leu1418Ser, or p.L1418S was found in the governing VCEP full-text files searched; this does not change the VCEP prohibition on PP5.
Sources
BP2 VCEPNot applicable: ENIGMA explicitly says BP2 is not to be used and is applied only in the context of BS2. Details ▾Hide ▴
Reasoning

The ENIGMA BRCA1 VCEP explicitly marks BP2 as not to be used and limits it to the context of BS2. BP2 is therefore not applicable as an independent criterion, regardless of whether any cis/trans co-observation is available.

VCEP rule
Observed in trans with a pathogenic variant for a fully penetrant dominant gene/disorder, or observed in cis with a pathogenic variant in any inheritance pattern ... Do not use ... Applied only in the context of BS2.
Evidence considered
  • ENIGMA VCEP Specifications Table 1 BP2 entry: BP2 is designated Do not use and is applied only in the context of BS2.
Still missing
  • Searched Specifications_V1.2_2024-11-18.docx.txt for c.4253T>C, p.Leu1418Ser, and p.L1418S; no variant-specific entry was found.
Sources
BP3 VCEPNot applicable: BP3 requires an in-frame deletion or insertion in a repetitive region, but c.4253T>C is a missense substitution. Details ▾Hide ▴
Reasoning

The variant is a missense substitution, not an in-frame deletion or insertion. The ENIGMA VCEP BP3 rule is limited to in-frame deletions/insertions in a repetitive region without a known function, so the repeat-region context cannot make BP3 applicable to Leu1418Ser.

VCEP rule
In-frame deletions/insertions in a repetitive region without a known function.
Evidence considered
  • Case normalization: NP_009225.1:p.(Leu1418Ser) is a missense substitution, not an in-frame insertion or deletion.
  • ENIGMA Specifications v1.2, Table 1, BP3 entry: 'In-frame deletions/insertions in a repetitive region without a known function'; the specification states that this is captured by bioinformatic tool prediction and domain analysis.
Still missing
  • No c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in Specifications_V1.2_2024-11-18.docx.txt.
  • No c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in Appendices_V1.2_2024-11-18.docx.txt.
  • No c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in Specifications_Table4_V1.2_2024-11-18.xlsx.txt.
  • No c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in PMID_22505045_Houdayer_2012_HumMutat.pdf.txt.
Sources
BP5 N/ANot applicable: Li et al. clinical-history LR 1.47600089290012 is above the BP5 supporting threshold of 0.48. Details ▾Hide ▴
Reasoning

The governing ENIGMA rule permits BP5 only for combined multifactorial clinical likelihood ratios against pathogenicity. The exact Li et al. 2020 row reports LR=1.47600089290012. For BP5 supporting, the VCEP operator is ≤0.48, and 1.47600089290012 ≤ 0.48? no. The VCEP further defines combined LR >0.48 and <2.08 as non-informative for PP4/BP5, so BP5 is not applicable.

VCEP rule
Use ONLY to capture combined LR against pathogenicity, based on multifactorial likelihood clinical data. BP5 - LR ≤0.48 to >0.23:1 Combined LR >0.48-1.00 is not informative (BP5 not applicable)
Evidence considered
  • Li et al. 2020 Supplementary Table 3, Sheet1 exact match: BRCA1 c.4253T>C; LOG(LR)=0.1690866202116013; N_Probands=1; LR=1.47600089290012.
  • The governing BP5 supporting operator is ≤; explicit comparison: 1.47600089290012 ≤ 0.48? no.
  • ENIGMA v1.2 states that combined LR >0.48 and <2.08 is not informative and BP5 is not applicable.
Still missing
  • No BP5-applicable combined multifactorial LR beyond the exact Li et al. clinical-history component was identified.
  • No entry for c.4253T>C, p.Leu1418Ser, or p.L1418S was found in Specifications_V1.2_2024-11-18.docx.txt, PMID_31853058_Li_2020_GeneticsInMedicine.pdf.txt, PMID_17924331_Easton_2007_AJHG.pdf.txt, or PMID_31853058_methods_supplement.docx.txt.
Sources
BP6 VCEPNot applicable: the ENIGMA BRCA1 VCEP explicitly marks BP6 as not for use. Details ▾Hide ▴
Reasoning

The ENIGMA BRCA1 VCEP explicitly marks BP6 as not applicable for this VCEP and states that the criterion is not for use as recommended by the ClinGen Sequence Variant Interpretation VCEP Review Committee.

VCEP rule
Reputable source recently reports variant as benign but the evidence is not available to the laboratory to perform an independent evaluation Do not use
Evidence considered
  • ENIGMA v1.2 BP6 entry marks the criterion "Not Applicable for this VCEP" and states: "This criterion is not for use as recommended by the ClinGen Sequence Variant Interpretation VCEP Review Committee."
Still missing
  • No entry for c.4253T>C, p.Leu1418Ser, or p.L1418S was found in the governing VCEP full-text files searched; this does not change the VCEP prohibition on BP6.
Sources
BP7 N/ANot applicable: the VCEP BP7 paths cover silent or intronic variants, whereas this variant is missense. Details ▾Hide ▴
Reasoning

The variant consequence is missense, not synonymous (silent) or intronic. The VCEP BP7 paths apply to silent variants inside a potentially clinically important functional domain, intronic variants outside conserved donor or acceptor motif positions if BP4 is met, or BP7_Strong (RNA) for mRNA-only functional studies in intronic, silent, or missense/in-frame variants outside a potentially clinically important functional domain. This variant is a missense substitution inside the coiled-coil domain and has no qualifying mRNA-only functional-study evidence for the BP7_Strong (RNA) path. BP7 is therefore not applicable before evidence sufficiency is considered. No variant-specific pre-assigned BP7 code was found in SupplementaryTables_V1.2_2024-11-18.xlsx.txt, Specifications_V1.2_2024-11-18.docx.txt, Appendices_V1.2_2024-11-18.docx.txt, or PMID_22505045_Houdayer_2012_HumMutat.pdf.txt.

VCEP rule
Apply BP7 for Silent variant inside a (potentially) clinically important functional domain, IF BP4 met. ... Intronic variants located outside conserved donor or acceptor motif positions (at or beyond positions +7/-21) IF BP4 met ... Apply as BP7_Strong (RNA) for intronic, silent, and missense/in-frame variants located outside a (potentially) clinically important functional domain.
Evidence considered
  • VCEP Specifications v1.2, BP7 applies to silent variants inside a potentially clinically important functional domain if BP4 is met, and to intronic variants outside conserved donor or acceptor motif positions if BP4 is met.
  • VCEP Specifications v1.2, BP7_Strong (RNA) applies to intronic, silent, and missense/in-frame variants located outside a potentially clinically important functional domain when supported by an mRNA-only functional study.
  • Case variant assessment: NM_007294.4:c.4253T>C, NP_009225.1:p.(Leu1418Ser), consequence class missense, exon 12; Appendix J places residue 1418 within the coiled-coil domain (aa 1391-1424).
Still missing
  • No c.4253T>C, p.Leu1418Ser, or p.L1418S entry or variant-specific pre-assigned BP7 code was found in SupplementaryTables_V1.2_2024-11-18.xlsx.txt.
  • No c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in Specifications_V1.2_2024-11-18.docx.txt.
  • No c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in Appendices_V1.2_2024-11-18.docx.txt.
  • No c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in PMID_22505045_Houdayer_2012_HumMutat.pdf.txt.
Sources

Identifiers

Gene
BRCA1
Transcript
NM_007294.4
Coding (HGVS c.)
NM_007294.4:c.4253T>C
Protein (HGVS p.)
NP_009225.1:p.(Leu1418Ser)
GRCh38
chr17:43082508 A>G
GRCh37
chr17:41234525 A>G
Location and type
Exon 12 · missense
ClinVar
1741675, 1715651, 629871, 246517

Gene diagram

Every interpreted variant in BRCA1, mapped onto the exon structure of NM_007294.4. Select a row to find it on the plot.

BRCA1NM_007294.4
Fetching transcript structure from UCSC…
gnomAD v4.1 1 / 1,614,190 alleles AF 6.2e-07 · 0 homozygotes
gnomAD v2.1 Allele count data not recorded
gnomAD-Canada v1.0 Allele count data not recorded

By genetic ancestry

gnomAD v4.1

AF 6.2e-07 · 1 / 1,614,190 alleles · 0 hom
European (non-Finnish)1 / 1,180,028 8.5e-07
0 alternate alleles recorded in 9 other groups: Remaining individuals, Admixed American, European (Finnish), Amish, East Asian, Middle Eastern, South Asian, Ashkenazi Jewish, African/African American.

Statements

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 6.19506e-07; MAF= 0.00006%, 1/1614190 alleles, homozygotes = 0) and has highest observed frequency in the European (non-Finnish) population (AF= 8.47438e-07; MAF= 0.00008%, 1/1180028 alleles, homozygotes = 0).

gnomAD v2.1

Absent from gnomAD v2.1.

gnomAD-Canada

Absent from gnomAD-Canada v1.0.

SpliceAI and Pangolin

SpliceAI acceptor lossat -49 bp
0.001
SpliceAI acceptor gainat +64 bp
0.010
SpliceAI donor lossat -106 bp
0.000
SpliceAI donor gainat -104 bp
0.001
Pangolin splice lossmagnitude shown
-0.008
Pangolin splice gain
0.004

Other predictors

REVEL
0.241
BayesDel
0.067

How the predictions were used

BP4 SupportingVCEPMet at Supporting: BayesDel 0.0666657 is ≤0.15 and SpliceAI max delta 0.01 is ≤0.1 for this coiled-coil missense variant. Details ▾Hide ▴
Reasoning

The variant is a missense substitution at p.(Leu1418Ser), within the VCEP-defined BRCA1 coiled-coil functional domain (aa 1391-1424), so the domain missense BP4 path applies. That path requires no predicted protein impact and no predicted splice impact: BayesDel no-AF ≤0.15 AND SpliceAI ≤0.1. The observed BayesDel score is 0.0666657 and the maximum SpliceAI delta score is 0.01; both satisfy the VCEP thresholds. No variant-specific pre-assigned BP4 code was found in SupplementaryTables_V1.2_2024-11-18.xlsx.txt, Specifications_V1.2_2024-11-18.docx.txt, Appendices_V1.2_2024-11-18.docx.txt, or PMID_22505045_Houdayer_2012_HumMutat.pdf.txt.

VCEP rule
Apply BP4 for: Missense or in-frame insertion, deletion or delins variants inside a (potentially) clinically important functional domain, and no predicted impact via protein change or splicing (BayesDel predicted No Impact AND SpliceAI ≤0.1). ... Missense Predictions (BayesDel no AF) BRCA1: No impact ≤ 0.15
Evidence considered
  • VCEP Specifications v1.2, BP4 rule for missense variants inside a potentially clinically important functional domain: BayesDel no-AF ≤0.15 AND SpliceAI ≤0.1.
  • Appendix J defines the BRCA1 coiled-coil domain as residues 1391-1424; p.(Leu1418Ser) is within that domain.
  • Case BayesDel no-AF result for NM_007294.4:c.4253T>C: 0.0666657, below the BRCA1 no-impact cutoff of 0.15.
  • Case SpliceAI result for NM_007294.4:c.4253T>C: maximum delta score 0.01, below the no-predicted-splicing-impact cutoff of 0.1.
Still missing
  • No c.4253T>C, p.Leu1418Ser, or p.L1418S entry or variant-specific pre-assigned BP4 code was found in SupplementaryTables_V1.2_2024-11-18.xlsx.txt.
  • No c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in Specifications_V1.2_2024-11-18.docx.txt.
  • No c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in Appendices_V1.2_2024-11-18.docx.txt.
  • No c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in PMID_22505045_Houdayer_2012_HumMutat.pdf.txt.
Sources
PP3 VCEPNot met: BayesDel 0.0666657 is below the VCEP PP3 threshold of ≥0.28 and SpliceAI 0.01 is below its ≥0.2 splice threshold. Details ▾Hide ▴
Reasoning

The variant is a missense substitution, p.(Leu1418Ser), at residue 1418 within the BRCA1 coiled-coil domain (aa 1391-1424), so both VCEP PP3 paths were evaluated. The protein-impact path requires BayesDel no-AF ≥0.28; the observed BayesDel score is 0.0666657, so that path is not met. The splice path applies to missense variants irrespective of functional-domain location and requires SpliceAI ≥0.2; the observed maximum SpliceAI delta score is 0.01, so that path is not met. No variant-specific pre-assigned PP3 code was found in SupplementaryTables_V1.2_2024-11-18.xlsx.txt, Specifications_V1.2_2024-11-18.docx.txt, Appendices_V1.2_2024-11-18.docx.txt, or PMID_22505045_Houdayer_2012_HumMutat.pdf.txt.

VCEP rule
Apply PP3 for missense or in-frame insertion, deletion or delins variants inside a (potentially) clinically important functional domain and predicted impact via protein change (BayesDel predicted Impact). ... Apply PP3 for predicted splicing (SpliceAI ≥0.2) for silent, missense/in-frame (irrespective of location in clinically important functional domain) and for intronic variants outside of the donor and acceptor ±1,2 positions. ... BRCA1: Impact ≥0.28
Evidence considered
  • VCEP Specifications v1.2, PP3 rule: missense or in-frame variants inside a potentially clinically important functional domain may use the protein-impact path with BayesDel predicted Impact; the BRCA1 threshold is Impact ≥0.28.
  • VCEP Specifications v1.2, PP3 rule: predicted splicing uses SpliceAI ≥0.2 for silent and missense/in-frame variants irrespective of location in a clinically important functional domain.
  • Appendix J defines the BRCA1 coiled-coil domain as residues 1391-1424; p.(Leu1418Ser) is within that domain.
  • Case SpliceAI result for NM_007294.4:c.4253T>C: DS_AG 0.01, DS_AL 0.001, DS_DG 0.001, DS_DL 0.0; maximum delta score 0.01.
  • Case BayesDel no-AF result for NM_007294.4:c.4253T>C: 0.0666657.
Still missing
  • No c.4253T>C, p.Leu1418Ser, or p.L1418S entry or variant-specific pre-assigned PP3 code was found in SupplementaryTables_V1.2_2024-11-18.xlsx.txt.
  • No c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in Specifications_V1.2_2024-11-18.docx.txt.
  • No c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in Appendices_V1.2_2024-11-18.docx.txt.
  • No c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in PMID_22505045_Houdayer_2012_HumMutat.pdf.txt.
Sources
BP7 N/ANot applicable: the VCEP BP7 paths cover silent or intronic variants, whereas this variant is missense. Details ▾Hide ▴
Reasoning

The variant consequence is missense, not synonymous (silent) or intronic. The VCEP BP7 paths apply to silent variants inside a potentially clinically important functional domain, intronic variants outside conserved donor or acceptor motif positions if BP4 is met, or BP7_Strong (RNA) for mRNA-only functional studies in intronic, silent, or missense/in-frame variants outside a potentially clinically important functional domain. This variant is a missense substitution inside the coiled-coil domain and has no qualifying mRNA-only functional-study evidence for the BP7_Strong (RNA) path. BP7 is therefore not applicable before evidence sufficiency is considered. No variant-specific pre-assigned BP7 code was found in SupplementaryTables_V1.2_2024-11-18.xlsx.txt, Specifications_V1.2_2024-11-18.docx.txt, Appendices_V1.2_2024-11-18.docx.txt, or PMID_22505045_Houdayer_2012_HumMutat.pdf.txt.

VCEP rule
Apply BP7 for Silent variant inside a (potentially) clinically important functional domain, IF BP4 met. ... Intronic variants located outside conserved donor or acceptor motif positions (at or beyond positions +7/-21) IF BP4 met ... Apply as BP7_Strong (RNA) for intronic, silent, and missense/in-frame variants located outside a (potentially) clinically important functional domain.
Evidence considered
  • VCEP Specifications v1.2, BP7 applies to silent variants inside a potentially clinically important functional domain if BP4 is met, and to intronic variants outside conserved donor or acceptor motif positions if BP4 is met.
  • VCEP Specifications v1.2, BP7_Strong (RNA) applies to intronic, silent, and missense/in-frame variants located outside a potentially clinically important functional domain when supported by an mRNA-only functional study.
  • Case variant assessment: NM_007294.4:c.4253T>C, NP_009225.1:p.(Leu1418Ser), consequence class missense, exon 12; Appendix J places residue 1418 within the coiled-coil domain (aa 1391-1424).
Still missing
  • No c.4253T>C, p.Leu1418Ser, or p.L1418S entry or variant-specific pre-assigned BP7 code was found in SupplementaryTables_V1.2_2024-11-18.xlsx.txt.
  • No c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in Specifications_V1.2_2024-11-18.docx.txt.
  • No c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in Appendices_V1.2_2024-11-18.docx.txt.
  • No c.4253T>C, p.Leu1418Ser, or p.L1418S entry was found in PMID_22505045_Houdayer_2012_HumMutat.pdf.txt.
Sources

Statement

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.01). REVEL score = 0.241. BayesDel score = 0.0666657.

5 paper records listed. No publication is explicitly linked to an applied criterion in the recorded metadata. None of the listed paper records explicitly indicates that the variant is named.

Recorded publications

  • Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.
    No paper-specific finding is recorded.
    PMID 23918944 ↗
  • BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer.
    Adam MP et al. · 1993
    No paper-specific finding is recorded.
    PMID 20301425 ↗
  • ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing.
    Green RC et al. · 2013
    This paper does not mention BRCA1 or the exact variant c.4253T>C / NP_009225.1:p.(L1418S), and provides no variant-specific functional, clinical, segregation, or population data relevant to PS4 or PP5.
    Does not name this variant
    PMID 23788249 ↗
    Quoted passage
    In fact, a novel missense mutation that may or may not be causative of the disorder, could be segregating with affected family members may (appropriately) not have been included in the report of incidental findings.

    Discussion, paragraph beginning ‘There is concern that incidental variant reporting could be misinterpreted...’

  • A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment.
    Hampel H et al. · 2015
    No paper-specific finding is recorded.
    PMID 25394175 ↗
  • Cancer Genetics Risk Assessment and Counseling (PDQ®): Health Professional Versi
    No paper-specific finding is recorded.
    PMID 26389258 ↗

Screenshots represent source records captured during evidence collection. Select one to view the recorded source content.

All source links

Statements for reports

The evidence statements recorded by the interpretation pipeline. They have not been reinterpreted by the page.

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 6.19506e-07; MAF= 0.00006%, 1/1614190 alleles, homozygotes = 0) and has highest observed frequency in the European (non-Finnish) population (AF= 8.47438e-07; MAF= 0.00008%, 1/1180028 alleles, homozygotes = 0).

gnomAD v2.1

Absent from gnomAD v2.1.

gnomAD-Canada

Absent from gnomAD-Canada v1.0.

ClinVar

This variant has been reported in ClinVar as Uncertain significance (4 clinical laboratories). (ClinVarID = 246517)

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.01). REVEL score = 0.241. BayesDel score = 0.0666657.

Functional

OncoKB did not identify variant-specific reviewed functional evidence for this variant; gene-level curated context is available for reviewer follow-up. BRCA1, a tumor suppressor involved in the DNA damage response, is mutated in various cancer types.

Somatic

This variant does not lie in a statistically significant hotspot. This variant has not previously been reported in somatic cancers (COSMIC).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.